Navigation Links
Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65
Date:2/27/2013

ing statements that may be made by the Company or by persons acting on its behalf and in conjunction with its periodic SEC filings. In addition, please refer to the cautionary note on forward-looking statements and risk factors set forth in the Company's  Report on Form 10-Q, for the quarter ended September 30, 2012, and in its other filings with the SEC. Further, uncertainties or other circumstances, or matters outside of the Company's control between the date of this release and the date that its Form 10-K for the year ended December 31, 2012, is filed with the SEC could potentially result in adjustments to reported results. The Company undertakes no obligation to update statements herein for revisions or changes after the date of this release. Mylan Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited; in thousands, except per share amounts) Three Months EndedDecember 31,Year EndedDecember 31,2012201120122011Revenues:Net revenues

$
,709,350$
,527,062$
,750,246$
,106,277Other revenues

13,5044,17245,86423,548Total revenues

1,722,8541,531,2346,796,1106,129,825Cost of sales

980,538886,6363,887,8063,566,461Gross profit

742,316644,5982,908,3042,563,364Operating expenses:Research and development

117,77076,077401,341294,728Selling, general and administrative

362,945301,0261,400,7471,214,631Litigation settlements, net

(1,049)20,099(3,133)48,556Total operating expenses

479,666397,2021,798,9551,557,915Earnings from operations

262,650247,3961,109,3491,005,449Interest expense

74,57381,108308,699335,944Other income (expense), net

2,779(37,412)3,429(14,869)Earnings before income taxes and noncontrolling interest

190,856128,876804,079654,636Income tax pro
'/>"/>

SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment of HIV/AIDS in South Africa
2. Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products
3. Mylan Schedules Fourth Quarter and Year End 2012 Financial Results Conference Call and Live Webcast
4. Mylan Appoints Melina Higgins and Rajiv Malik to Board of Directors
5. Mylan Announces Pricing of Senior Notes
6. Moodys and Standard & Poors Upgrade Mylan to Investment Grade Credit Ratings
7. Mylan Reports a 51% Increase in Third Quarter 2012 Adjusted Diluted EPS to $0.83
8. Mylan Selected as a Leading ARV Supplier to Indias National AIDS Control Organization
9. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
10. Mylan Launches Lithium Carbonate Extended-Release Tablets USP
11. Mylan Launches Commercial Operations in India, Starting with a Broad, Innovative Portfolio of ARV Products to Treat HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant ... TSX: VRX) announced that the applicable waiting period under ... respect to the previously announced tender offer by its ... of the outstanding shares of common stock of Solta ... a price of $2.92 per share, net to the ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... A drug delivery system is ...
(Date:1/15/2014)... -- A novel wearable injector slightly larger than an Oreo ... patients to self-inject prescription drugs in the large doses ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   ... of injector that does not exist today for self-administration ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... 20 Thomson Reuters, a global provider ... the newest version of its award-winning Clinical ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090507/NY12658LOGO) (Logo: ... hospital-based clinicians to access complete patient clinical ...
... VPHM ) third quarter financial results for 2010 ... before the open of the U.S. financial markets. ... webcast at 9:00 a.m. Eastern Time on the same day. ... third quarter financial results and other business. ...
Cached Medicine Technology:Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 2Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 3ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Feb. 8 Aton Pharma, Inc., a diversified ... has joined the company as Vice President, Commercial Operations ... A. Fishbein assumes the same role for the Ophthalmic ... LLC, Aton is focused on the development and commercialization of ...
... , , , , , ... , Feb. 8 /PRNewswire-Asia-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink ... of botanical products,bio-pharmaceuticals and traditional Chinese medicines ("TCM"), announced today,that ... the fiscal year ended, October 31, 2009 on time. ...
... ... Corporation (Pinksheets: NUEC) (“NuEarth”), a manufacturer and marketer of "Clean ... Laboratory and Research Division “TerraSolv SA” has received final approval ... additional $1.3 Million laboratory service contract with the Nigerian National ...
... in the gut, triggering bone formation , MONDAY, Feb. 8 ... the gut cured osteoporosis in lab mice and rats, a ... serotonin in the gut hinders bone formation. Most current drugs ... build bone. , "New therapies that inhibit the production of ...
... divide abnormally, researchers say , MONDAY, Feb. 8 (HealthDay News) ... week may have double the risk of developing deadly pancreatic ... But the overall number of people developing the malignancy remains ... new cases last year. , "Soft drinks are linked with ...
... , WOONSOCKET, ... CVS ) today announced record revenues, operating profit, and ... ended December 31, 2009 . , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) ... of 2009, increased $1.7 billion to $25.8 billion , up ...
Cached Medicine News:Health News:Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 3Health News:NuEarth Signs $1.3 Million Laboratory Contract 2Health News:NuEarth Signs $1.3 Million Laboratory Contract 3Health News:Drug Cures Osteoporosis in Mice 2Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 2Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 3Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 4Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 2Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 3Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 4Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 5Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 6Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 7Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 8Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 9Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 10Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 11Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 12Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 13Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 14Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 15Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 16Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 17Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 18Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 19Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 20Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 21Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 22Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 23Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 24Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 25Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 26
For the quantitative determination of total cholesterol in human serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products: